Oncology Drugs Market By Drug Class Type (Targeted Drugs, Chemotherapy Drugs, Immunotherapy, and Hormonal Therapy Drugs), By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer, Prostate Cancer, and Others), By Distribution Channel (Hospitals Pharmacies, Online Pharmacies, and Retail Pharmacies), Industry Trends, Estimation & Forecast, 2020-2026

Global oncology drugs market was valued at $95.4 billion in 2019 with a CAGR of 7.6% from 2020 to 2026.
  • Market Definition

    Oncology drug is used for cancer treatment. Oncology drug kills the cancer cells or stops them from growing and spreading to other parts of your body. Oncology drug class type includes Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy.

    Global oncology drugs market is estimated to reach $XX million by 2026; growing at a CAGR of XX% till 2026.

    Market Dynamics

    Rising prevalence of cancer is boosting the oncology drugs market. For instance, according to the American Institute for Cancer Research, breast cancer is the second most common cancer globally. Globally, around 2 million new cases of breast cancer are diagnosed in 2018. Around 627,000 women died from breast cancer, which is approximately 15% of all cancer deaths among women in 2018. According to the American Cancer Society, it is estimated that in 2020 there will be 191,930 new cases of prostate cancer and 33,330 deaths from prostate cancer in the United States. According to the World Health Organization (WHO), globally, lung cancer accounts for 2.09 million cases in 2018. According to the American Cancer Society, in 2020, an estimated 228,820 new cases of lung cancer were diagnosed in the United States. According to the World Health Organization (WHO), globally, colorectal cancer accounts for 1.80 million cases in 2018. According to the American Cancer Society’s (ACS), in 2020, an estimate of 147,950 adults in the United States are expected to diagnose with colorectal cancer. According to the World Health Organization (WHO), every year, around 900,000 people worldwide are diagnosed with blood cancer. Further, increasing clinical studies on oncology drugs is a key driving factor of the market. However, the adverse effects associated with cancer drugs might hamper market growth. Some of the common side effects of cancer drugs include low blood counts causes an increased possibility of developing infection or anemia, tiredness, mouth soreness, nausea, vomiting, hair loss, skin changes or reactions, pain or nerve changes, and more. Moreover, increasing investment by the government and pharmaceutical companies for research and development of oncology drugs would provide lucrative opportunities for the market in the coming years.

    Market Segmentation

    The global oncology drugs market is mainly classified based on drug class type, application, and distribution channel. Drug Class Type is further segmented into Targeted Drugs, Chemotherapy Drugs, Immunotherapy, and Hormonal Therapy Drugs. By application, the market is divided into Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer, Prostate Cancer, and Others. By distribution channels, the market is further divided into Hospitals Pharmacies, Online Pharmacies, and Retail Pharmacies.

    The targeted drug was dominating the oncology drugs market in 2019, owing to the increasing research and development activities for targeted drugs, rising investment for development and commercialization of oncology drugs, and regulatory approval of targeted drugs for cancer treatment. For instance, the U.S. Food and Drug Administration has approved Tabrecta (capmatinib) for the treatment of non-small cell lung cancer (NSCLC) for adult patients. Tabrecta is the first FDA-approved therapy to treat NSCLC with specific mutations.

    Regional Analysis

    Based on geography, the global oncology drugs market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

    North America was dominating the oncology drugs market in 2019, due to the rising prevalence of cancer in North American region, increasing clinical studies on oncology drugs, commercialization of regulatory approved oncology drugs, and increasing investment for the development of oncology drugs. For instance, Palleon Pharmaceuticals focused on developing Glycoimmune Checkpoint Inhibitors to treat cancer, have received $47.6 million investment from SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures, and AbbVie Ventures. The investment is used to establish the first-in-class pipeline of drug candidates targeting Glycoimmune Checkpoints to create immunosuppression that allows tumors to thrive.

    Competitive landscape

    Key players operating in the oncology drugs industry include Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc, Novartis AG, Bristol-Myers Squibb Company, Astellas Pharma Inc., AstraZeneca PLC, AbbVie Inc., and Eli Lilly and Company.

    The rising investment by the companies for the development of oncology drugs, increasing regulatory approval for oncology drugs, the partnership between companies to develop and supply oncology drugs and extend the market presence, increasing clinical studies on oncology drugs, and commercialization of new oncology drugs are some of the strategies adopted by the major companies. For instance, on January 23, 2020, Pfizer has introduced three new oncology biosimilars to the US market. The three biosimilars include bevacizumab-bvzr (Zirabev), rituximab-pvvr (Ruxience), and trastuzumab-qyyp (Trazimera).

    Bevacizumab-bvzr is used for the treatment of metastatic colorectal cancer, non-small cell lung cancer, metastatic renal cell carcinoma, recurrent glioblastoma, and metastatic cervical cancer. Rituximab-pvvr is indicated for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis in adults. Trastuzumab-qyyp is indicated for the use of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and gastroesophageal junction adenocarcinoma.

    Oncology Drugs Market Key Segments:

    By Drug Class Type
    • Targeted Drugs
    • Chemotherapy Drugs
    • Immunotherapy
    • Hormonal Therapy Drugs

    By Application
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Blood Cancer
    • Prostate Cancer
    • Others

    By Distribution Channel
    • Hospitals Pharmacies
    • Online Pharmacies
    • Retail Pharmacies

    Key Global Oncology Drugs Industry Players
    • Pfizer Inc.
    • Johnson & Johnson
    • Roche Holding AG
    • Merck & Co. Inc
    • Novartis AG
    • Bristol-Myers Squibb Company
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • AbbVie Inc.
    • Eli Lilly and Company

    keyboard_arrow_up
  • Table of Content

    1. Market Introduction
    1.1. Executive Summary
    1.2. Market Definition
    1.3. Market Scope

    2. Research Methodology
    2.1. Primary Research
    2.2. Research Methodology
    2.3. Assumptions & Exclusions
    2.4. Secondary data sources

    3. Oncology Drugs Market Overview
    3.1. Report Segmentation & Scope
    3.2. Key Market Trend
    3.3. Drivers
    3.3.1. Rising Prevalence of Cancer
    3.3.2. Increasing Clinical Studies on Oncology Drugs
    3.4. Restraints
    3.4.1. Adverse Effects Associated with Cancer Drugs
    3.5. Opportunity
    3.5.1. Increasing Investment by the Government and Pharmaceutical Companies for Research and Development of Oncology Drugs
    3.6. Porter’s Five Forces Analysis
    3.6.1. Porter’s Five Forces Analysis
    3.7. Market Share Analysis

    4. Drug Class Type Overview
    4.1. Introduction
    4.1.1. Market Size & Forecast
    4.2. Targeted Drugs
    4.2.1. Market Size & Forecast
    4.3. Chemotherapy Drugs
    4.3.1. Market Size & Forecast
    4.4. Immunotherapy
    4.4.1. Market Size & Forecast
    4.5. Hormonal Therapy Drugs
    4.5.1. Market Size & Forecast

    5. Application Overview
    5.1. Introduction
    5.1.1. Market Size & Forecast
    5.2. Breast Cancer
    5.2.1. Market Size & Forecast
    5.3. Colorectal Cancer
    5.3.1. Market Size & Forecast
    5.4. Lung Cancer
    5.4.1. Market Size & Forecast
    5.5. Blood Cancer
    5.5.1. Market Size & Forecast
    5.6. Prostate Cancer
    5.6.1. Market Size & Forecast
    5.7. Others
    5.7.1. Market Size & Forecast

    6. Distribution Channel Overview
    6.1. Introduction
    6.1.1. Market Size & Forecast
    6.2. Hospitals Pharmacies
    6.2.1. Market Size & Forecast
    6.3. Online Pharmacies
    6.3.1. Market Size & Forecast
    6.4. Retail Pharmacies
    6.4.1. Market Size & Forecast

    7. Oncology Drugs Market Regional Overview
    7.1. Introduction
    7.1.1. Market Size & Forecast
    7.2. North America Oncology Drugs Market
    7.2.1. North America Market Size & Forecast, By Country
    7.2.2. North America Market Size & Forecast, By Drug Class Type
    7.2.3. North America Market Size & Forecast, By Application
    7.2.4. North America Market Size & Forecast, By Distribution Channel
    7.2.5. U.S.
    7.2.5.1. Market Size and Forecast
    7.2.6. Canada
    7.2.6.1. Market Size and Forecast
    7.2.7. Mexico
    7.2.7.1. Market Size and Forecast
    7.3. Europe Oncology Drugs Market
    7.3.1. Europe Market Size & Forecast, By Country
    7.3.2. Europe Market Size & Forecast, By Drug Class Type
    7.3.3. Europe Market Size & Forecast, By Application
    7.3.4. Europe Market Size & Forecast, By Distribution Channel
    7.3.5. Germany
    7.3.5.1. Market Size and Forecast
    7.3.6. France
    7.3.6.1. Market Size and Forecast
    7.3.7. UK
    7.3.7.1. Market Size and Forecast
    7.3.8. Italy
    7.3.8.1. Market Size and Forecast
    7.3.9. Spain
    7.3.9.1. Market Size and Forecast
    7.3.10. Rest of Europe
    7.3.10.1. Market Size and Forecast
    7.4. Asia-Pacific Oncology Drugs Market
    7.4.1. Asia-Pacific Market Size & Forecast, By Country
    7.4.2. Asia-Pacific Market Size & Forecast, By Drug Class Type
    7.4.3. Asia-Pacific Market Size & Forecast, By Application
    7.4.4. Asia-Pacific Market Size & Forecast, By Distribution Channel
    7.4.5. Japan
    7.4.5.1. Market Size and Forecast
    7.4.6. China
    7.4.6.1. Market Size and Forecast
    7.4.7. Australia
    7.4.7.1. Market Size and Forecast
    7.4.8. India
    7.4.8.1. Market Size and Forecast
    7.4.9. South Korea
    7.4.9.1. Market Size and Forecast
    7.4.10. Rest of Asia-Pacific
    7.4.10.1. Market Size and Forecast
    7.5. South America Oncology Drugs Market
    7.5.1. South America Market Size & Forecast, By Country
    7.5.2. South America Market Size & Forecast, By Drug Class Type
    7.5.3. South America Market Size & Forecast, By Application
    7.5.4. South America Market Size & Forecast, By Distribution Channel
    7.5.5. Brazil
    7.5.5.1. Market Size and Forecast
    7.5.6. Argentina
    7.5.6.1. Market Size and Forecast
    7.5.7. Rest of South America
    7.5.7.1. Market Size and Forecast
    7.6. Middle East & Africa Oncology Drugs Market
    7.6.1. Middle East & Africa Market Size & Forecast, By Country
    7.6.2. Middle East & Africa Market Size & Forecast, By Drug Class Type
    7.6.3. Middle East & Africa Market Size & Forecast, By Application
    7.6.4. Middle East & Africa Market Size & Forecast, By Distribution Channel
    7.6.5. GCC Countries
    7.6.5.1. Market Size and Forecast
    7.6.6. Egypt
    7.6.6.1. Market Size and Forecast
    7.6.7. South Africa
    7.6.7.1. Market Size and Forecast
    7.6.8. Rest of Middle East & Africa
    7.6.8.1. Market Size and Forecast

    8. Company Profile
    8.1. Pfizer Inc.
    8.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    8.1.2. Pfizer Inc. Product Category, Application, and Specification
    8.1.3. Pfizer Inc. Financial Performance (2016-2018)
    8.1.4. Main Business/Business Overview
    8.2. Johnson & Johnson
    8.3. Roche Holding AG
    8.4. Merck & Co. Inc
    8.5. Novartis AG
    8.6. Bristol-Myers Squibb Company
    8.7. Astellas Pharma Inc.
    8.8. AstraZeneca PLC
    8.9. AbbVie Inc.
    8.10. Eli Lilly and Company

    keyboard_arrow_up


    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

What Report Provides?

• Full in-depth analysis of the parent Industry
• Important changes in market and its dynamics
• Segmentation details of the market
• Former, on-going, and projected market analysis in terms of volume and value
• Assessment of niche industry developments
• Market share analysis
• Key strategies of major players
• Emerging segments and regional growth potential

error: Right-Click on this site is Disabled